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signiﬁcantly (p = 0.0432) higher costs for cilostazol using a
gamma GLM model. CONCLUSIONS: The gamma GLM tech-
nique is a powerful tool for modeling strictly positive skewed
outcomes and should be more widely employed in pharma-
coeconomic analyses.
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To design a cost-effectiveness trial, the Delta-K method newly
developed provides us with a new formula for sample-size 
calculation. The Delta-K utilizes the difference between two 
cost-effectiveness ratios, qA and qB, respectively of control and
experimental regimens (i.e., KD = 1/qA - 1/qB). The advantage of
the method is simplicity for estimating the sample-size, naturally
extending the conventional binomial formula, whereas under the
assumption of “econstant” cost for each regimen. OBJECTIVES:
Using multivariate analysis with the Monte-Carlo simulation for
“evariable” costs, we assess the robustness of the Delta-K
method in search of the probable range of sample-sizes calcu-
lated based on the formula. METHOD: A case study of cost-
consequence analysis is employed to validate the design of a
clinical trial, which evaluates herpes zoster treatment with
Valaciclovir vs. Aciclovir. Our former investigation on this case
illuminated that the sample-size for the RCT could be reduced
from n = 821 to n = 36 in use of the Delta-K method regarding
the average costs as constant. In the Monte-Carlo simulation,
therefore, the three major factors of costs such as primary med-
ication, treatment for post herpes neuralgia (PHN), and outpa-
tient care were assumed to have a normal distribution since each
factor is quantiﬁed with the mean and the standard deviation
(S.D.)(e.g., for PHN; US$1504.9 ± 6.1 in Valaciclovir, whereas
US$2006.6 ± 6.6 in Aciclovir). Under these conditions Monte-
Carlo simulation was run up to 10,000 times to assess the overall
distribution of sample-sizes calculated from the formula.
RESULTS: The runs of 10,000 times resulted in the distribution
with the sample-size of 35.2 ± 0.8(the mean ± 2S.D.) and the
range of (33.7, 37.0) = (min, max), which is far smaller than the
original sample-size n = 821. CONCLUSION: We conﬁrmed suf-
ﬁcient robustness of the Delta-K method in a case study even if
medical costs vary against the assumption of constant cost. It
suggests the usefulness of the new method.
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The concept of incremental cost effectiveness ratios (ICERs) and
conﬁdence intervals (CIs) may seem complicated to many prac-
titioners and decision makers. There is a growing body of liter-
ature regarding the use of NNT (number needed to treat) as a
statistic that may be easier to understand in clinical practice.
NNTs and ICERs are receiving increased attention in the 
interface of clinical and economic concepts. OBJECTIVE: To
compare the ICER and CI results by using NNT-related calcula-
tions versus bootstrap analyses utilizing datasets from three pub-
lished papers. METHODS: An NNT spreadsheet calculator was
developed that generates NNT conﬁdence intervals and incre-
mental cost to treat calculations. Datasets with an aggregate total
of over 2000 patients from three previously published pharma-
coeconomic studies were analyzed with both the NNT and boot-
strap ICER approach. The NNT calculator used a two by two
contingency table with additional cells for including cost of each
treatment. Conﬁdence intervals (95%) were calculated for NNT
and the upper and lower values of the incremental cost per suc-
cessfully treated patient. In contrast, the bootstrap software uti-
lizes each individual patient case in the datasets to generate ICER
ratios and ICER conﬁdence intervals. RESULTS: The NNT
results for the mean cost needed to treat for one successful
outcome showed good agreement with the bootstrap generated
ICER slopes. For NNT versus bootstrap, the anti-platelet study
mean ICERs were $43,729 vs. $43,742, the antidepressant 
comparative study ICERs were -$1648 vs. -$1647 and the 
antidepressant combination study ICERs were -$188,014 vs. 
-$188,012. Using 5th and 95th percentiles for cost of treatment
multiplied by corresponding NNT conﬁdence intervals did not
generate very close agreement with the bootstrapped CIs. CON-
CLUSIONS: NNT related calculations may be a method for ini-
tially analyzing local pilot data or explore the economic
ramiﬁcations of a clinical publication when the full dataset is not
available.
PMD4
ISHIKAWA CAUSE AND EFFECT DIAGRAMS:A USEFUL TOOL
IN DESIGNING ECONOMIC ANALYSES
Salvador CG1, Goldfarb N2
1Jefferson Medical College, Philadelphia, PA, USA; 2Thomas Jefferson
University, Philadelphia, PA, USA
OBJECTIVES: Cause and effect diagrams (also known as
Ishikawa or ﬁshbone diagrams) graphically depict the relation-
ships between a particular outcome and all of the identiﬁed
factors contributing to that outcome. The diagram’s structure
includes a central “bone” with the topic of interest (the “head”)
attached at the right-hand end. Branching out from the central
line are “sub-bones” that represent primary causal factors, and
each of these in turn has sub-bones representing subsidiary con-
tributing factors. METHODS: Ishikawa diagrams were origi-
nally developed and have typically been used as a tool for root
cause analyses, but they also can beneﬁt the planning of eco-
nomic analyses for a particular disease state, medical technology,
or other health care intervention. Recent projects conducted by
the Department of Health Policy of Jefferson Medical College
illustrate the value of Ishikawa diagrams in planning economic
analyses. One project involved the development of an economic
model related to the diagnosis and management of Crohn’s
disease. An Ishikawa diagram was used to organize the ﬁndings
of an extensive literature review on this topic. The main cate-
gories, or “sub-bones” contributing to the cost of Crohn’s
included: diagnostic work-up, medication therapy, administra-
tion, hospitalization, surgery, and adverse reactions/complica-
tions. RESULTS: Many of these categories were further broken
down into appropriate subcategories. In another project, this
tool was used to organize and graphically depict cost factors for
allogeneic blood transfusions. Identiﬁed factors contributing to
total costs were organized around four main sub-bones: Acqui-
sition, Administration, Preparation, and Adverse Events/Com-
plications. CONCLUSIONS: In both of these projects, the
constructed diagram facilitated the organization of large
amounts of information, selection of key factors for inclusion in
decision analytic economic models, and identiﬁcation of unmea-
sured contributors to cost, which might inﬂuence the model’s
assumptions or ﬁndings. Outcomes researchers therefore are
